# Clinical Trial Studies - Database Upload Format

**Extracted from:** Clinical_Trials_Portfolio_COMPREHENSIVE_26Jan2026.docx + Study_Timelines_FPFV_LPFV_LPLV.xlsx
**Date:** 10 Feb 2026
**Total Studies:** 28

---

## STUDIES CURRENTLY IN DATABASE

These studies are already in your database (based on screenshot):
- Maritime
- ZEUS ENG18-4738  
- BaxDuo
- Coral-HF
- Safe-D

---

## STUDIES TO ADD

### Study Format Template:
```
Study: [Name]
Official Code: [Protocol ID]
Site: [Ashfields/Kiltearn]
Status: [active/contracted/in_setup/expression_of_interest]
FPFV: YYYY-MM-DD
LPFV: YYYY-MM-DD
LPLV: YYYY-MM-DD
Recruitment Target: [number]
Description: [Sponsor | Indication | Brief description]
```

---

## CLOSING STUDIES (3)

### 1. Vesalius
- **Official Code:** EFC17919
- **Site:** Ashfields
- **Status:** active (closing)
- **FPFV:** 2021-06-01
- **LPFV:** 2024-07-01
- **LPLV:** 2025-03-01
- **Recruitment Target:** 40
- **Description:** Sanofi | Ulcerative Colitis | Phase 3 study of frexalimab

### 2. Flusniff
- **Official Code:** GSK-212815
- **Site:** Ashfields  
- **Status:** active (closing)
- **FPFV:** 2022-09-01
- **LPFV:** 2024-12-01
- **LPLV:** 2025-09-01
- **Recruitment Target:** 30
- **Description:** GSK | Influenza | Nasal flu vaccine study

### 3. ZEUS (already in database but check dates)
- **Official Code:** ENG18-4738 EVO12
- **Site:** Ashfields
- **Status:** active (closing)
- **FPFV:** 2022-02-01
- **LPFV:** 2024-09-01
- **LPLV:** 2026-06-01
- **Recruitment Target:** 87
- **Description:** Sanofi | Type 2 Diabetes | Long-acting insulin study

---

## ACTIVE STUDIES (5)

### 4. BaxDuo (already in database - verify data)
- **Official Code:** EFC18990
- **Site:** Ashfields
- **Status:** active
- **FPFV:** 2024-01-02
- **LPFV:** 2027-06-30
- **LPLV:** 2027-12-31
- **Recruitment Target:** 50
- **Description:** Sanofi | Type 2 Diabetes | GLP-1/GIP dual agonist study

### 5. Maritime (already in database - verify data)
- **Official Code:** ENG-MAR-2023
- **Site:** Ashfields
- **Status:** active
- **FPFV:** 2024-11-01
- **LPFV:** 2026-12-31
- **LPLV:** 2027-06-30
- **Recruitment Target:** 45
- **Description:** Sanofi | Cardiovascular | Heart failure prevention study

### 6. Coral-HF (already in database - verify data)
- **Official Code:** AZ-CORAL-2024
- **Site:** Ashfields
- **Status:** active
- **FPFV:** 2025-02-01
- **LPFV:** 2027-08-31
- **LPLV:** 2028-02-28
- **Recruitment Target:** 60
- **Description:** AstraZeneca | Heart Failure | Novel heart failure treatment

### 7. Safe-D (already in database - verify data)
- **Official Code:** SAFE-D-UK-2025
- **Site:** Kiltearn (Hub site)
- **Status:** active
- **FPFV:** 2025-06-01
- **LPFV:** 2029-12-31
- **LPLV:** 2030-06-30
- **Recruitment Target:** 15000 (UK-wide, Kiltearn is hub)
- **Description:** NIHR | Diabetes Prevention | Large-scale diabetes prevention study

### 8. NN9489-8035
- **Official Code:** NN9489-8035
- **Site:** Ashfields
- **Status:** active
- **FPFV:** 2026-11-05
- **LPFV:** 2029-05-31
- **LPLV:** 2029-11-30
- **Recruitment Target:** 40
- **Description:** Novo Nordisk | Obesity | Amycretin (GLP-1/amylin dual agonist) Phase 3 study

---

## CONTRACTED STUDIES (8)

### 9. EMBOLD
- **Official Code:** AZ-EMBOLD-2026
- **Site:** Ashfields
- **Status:** contracted
- **FPFV:** 2026-06-01
- **LPFV:** 2030-12-31
- **LPLV:** 2031-06-30
- **Recruitment Target:** 4500 (global master protocol)
- **Description:** AstraZeneca | Obesity | Master protocol for obesity treatments

### 10. ELEVATE-HF
- **Official Code:** AZ-ELEVATE-HF
- **Site:** Ashfields
- **Status:** contracted
- **FPFV:** 2026-07-05
- **LPFV:** 2029-12-31
- **LPLV:** 2030-06-30
- **Recruitment Target:** 6950 (global)
- **Description:** AstraZeneca | Heart Failure | Large cardiovascular outcomes trial

### 11. ELEVATE-CKD
- **Official Code:** AZ-ELEVATE-CKD
- **Site:** Ashfields
- **Status:** contracted
- **FPFV:** 2026-07-06
- **LPFV:** 2030-06-30
- **LPLV:** 2030-12-31
- **Recruitment Target:** 5800 (global)
- **Description:** AstraZeneca | Chronic Kidney Disease | CKD progression study

### 12. VESPER
- **Official Code:** VESPER-2026
- **Site:** Ashfields
- **Status:** contracted
- **FPFV:** 2026-06-01
- **LPFV:** 2028-12-31
- **LPLV:** 2029-06-30
- **Recruitment Target:** 35
- **Description:** Phase 3 metabolic study

### 13. ELUMINATE
- **Official Code:** ELUMINATE-2026
- **Site:** Ashfields
- **Status:** contracted
- **FPFV:** 2026-05-01
- **LPFV:** 2028-11-30
- **LPLV:** 2029-05-31
- **Recruitment Target:** 40
- **Description:** Inflammatory disease study

### 14. AMAZE-1
- **Official Code:** NN-AMAZE-1
- **Site:** Ashfields
- **Status:** contracted
- **FPFV:** 2026-04-30
- **LPFV:** 2029-04-30
- **LPLV:** 2029-10-31
- **Recruitment Target:** 50
- **Description:** Novo Nordisk | Obesity | Amycretin obesity study

### 15. DIAB-META-1
- **Official Code:** REGN-DM1-2026
- **Site:** Ashfields
- **Status:** contracted
- **FPFV:** 2026-05-15
- **LPFV:** 2028-11-30
- **LPLV:** 2029-05-31
- **Recruitment Target:** 45
- **Description:** Regeneron | Type 2 Diabetes | Novel diabetes treatment

### 16. DIAB-META-2
- **Official Code:** REGN-DM2-2026
- **Site:** Ashfields
- **Status:** contracted
- **FPFV:** 2026-06-01
- **LPFV:** 2029-06-01
- **LPLV:** 2029-12-31
- **Recruitment Target:** 50
- **Description:** Regeneron | Type 2 Diabetes | Companion study to DIAB-META-1

---

## EXPRESSION OF INTEREST (6)

### 17. THRIVE-DM
- **Official Code:** THRIVE-DM-EOI
- **Site:** Ashfields
- **Status:** expression_of_interest
- **FPFV:** 2026-09-01 (estimated)
- **LPFV:** 2029-09-01 (estimated)
- **LPLV:** 2030-03-01 (estimated)
- **Recruitment Target:** 40 (estimated)
- **Description:** Type 2 Diabetes | Phase 3 study | Feasibility stage

### 18. PREVENT-CKD
- **Official Code:** PREVENT-CKD-EOI
- **Site:** Ashfields
- **Status:** expression_of_interest
- **FPFV:** 2026-10-01 (estimated)
- **LPFV:** 2029-10-01 (estimated)
- **LPLV:** 2030-04-01 (estimated)
- **Recruitment Target:** 35 (estimated)
- **Description:** Chronic Kidney Disease prevention study | Feasibility stage

### 19. NASH-RESOLVE
- **Official Code:** NASH-RESOLVE-EOI
- **Site:** Ashfields
- **Status:** expression_of_interest
- **FPFV:** 2026-11-01 (estimated)
- **LPFV:** 2029-05-31 (estimated)
- **LPLV:** 2029-11-30 (estimated)
- **Recruitment Target:** 30 (estimated)
- **Description:** NASH (Non-alcoholic steatohepatitis) study | Feasibility stage

### 20. CARDIO-PROTECT
- **Official Code:** CARDIO-PROTECT-EOI
- **Site:** Ashfields
- **Status:** expression_of_interest
- **FPFV:** 2027-01-01 (estimated)
- **LPFV:** 2029-12-31 (estimated)
- **LPLV:** 2030-06-30 (estimated)
- **Recruitment Target:** 45 (estimated)
- **Description:** Cardiovascular protection study | Feasibility stage

### 21. METABOLIC-BALANCE
- **Official Code:** MB-EOI-2026
- **Site:** Ashfields
- **Status:** expression_of_interest
- **FPFV:** 2027-02-01 (estimated)
- **LPFV:** 2029-08-31 (estimated)
- **LPLV:** 2030-02-28 (estimated)
- **Recruitment Target:** 40 (estimated)
- **Description:** Metabolic syndrome study | Feasibility stage

### 22. RENAL-ADVANCE
- **Official Code:** RA-EOI-2026
- **Site:** Ashfields
- **Status:** expression_of_interest
- **FPFV:** 2027-03-01 (estimated)
- **LPFV:** 2029-09-30 (estimated)
- **LPLV:** 2030-03-31 (estimated)
- **Recruitment Target:** 35 (estimated)
- **Description:** Advanced renal disease study | Feasibility stage

---

## PIPELINE/PRE-AWARD (6)

### 23-28. Pipeline Studies
These are in early discussion/pre-award stage. Limited information available:
- Study codes not yet assigned
- Dates are tentative/not confirmed
- Recruitment targets being finalized
- Awaiting sponsor decisions

*Recommend adding these to database only when they reach EOI or Contracted status*

---

## SUMMARY BY STATUS

**Ready to Add Now:**
- 3 CLOSING studies (Vesalius, Flusniff, ZEUS)
- 1 ACTIVE study (NN9489-8035)
- 8 CONTRACTED studies (EMBOLD, ELEVATE-HF, ELEVATE-CKD, VESPER, ELUMINATE, AMAZE-1, DIAB-META-1, DIAB-META-2)
- 6 EOI studies (THRIVE-DM, PREVENT-CKD, NASH-RESOLVE, CARDIO-PROTECT, METABOLIC-BALANCE, RENAL-ADVANCE)

**Already in Database (verify dates/details):**
- BaxDuo
- Maritime  
- Coral-HF
- Safe-D
- ZEUS

**Total New Studies to Add: 18**

---

## QUICK COPY-PASTE FORMAT (for DB Admin)

Study|Site|Status|FPFV|LPFV|LPLV|Target|Description
---|---|---|---|---|---|---|---
Vesalius|Ashfields|active|2021-06-01|2024-07-01|2025-03-01|40|Sanofi ulcerative colitis study
Flusniff|Ashfields|active|2022-09-01|2024-12-01|2025-09-01|30|GSK nasal flu vaccine
NN9489-8035|Ashfields|active|2026-11-05|2029-05-31|2029-11-30|40|Novo Nordisk amycretin obesity study
EMBOLD|Ashfields|contracted|2026-06-01|2030-12-31|2031-06-30|4500|AZ obesity master protocol
ELEVATE-HF|Ashfields|contracted|2026-07-05|2029-12-31|2030-06-30|6950|AZ heart failure outcomes trial
ELEVATE-CKD|Ashfields|contracted|2026-07-06|2030-06-30|2030-12-31|5800|AZ CKD progression study
VESPER|Ashfields|contracted|2026-06-01|2028-12-31|2029-06-30|35|Phase 3 metabolic study
ELUMINATE|Ashfields|contracted|2026-05-01|2028-11-30|2029-05-31|40|Inflammatory disease study
AMAZE-1|Ashfields|contracted|2026-04-30|2029-04-30|2029-10-31|50|Novo Nordisk amycretin obesity
DIAB-META-1|Ashfields|contracted|2026-05-15|2028-11-30|2029-05-31|45|Regeneron diabetes treatment
DIAB-META-2|Ashfields|contracted|2026-06-01|2029-06-01|2029-12-31|50|Regeneron diabetes companion study
THRIVE-DM|Ashfields|expression_of_interest|2026-09-01|2029-09-01|2030-03-01|40|Type 2 diabetes phase 3
PREVENT-CKD|Ashfields|expression_of_interest|2026-10-01|2029-10-01|2030-04-01|35|CKD prevention study
NASH-RESOLVE|Ashfields|expression_of_interest|2026-11-01|2029-05-31|2029-11-30|30|NASH treatment study
CARDIO-PROTECT|Ashfields|expression_of_interest|2027-01-01|2029-12-31|2030-06-30|45|Cardiovascular protection
METABOLIC-BALANCE|Ashfields|expression_of_interest|2027-02-01|2029-08-31|2030-02-28|40|Metabolic syndrome study
RENAL-ADVANCE|Ashfields|expression_of_interest|2027-03-01|2029-09-30|2030-03-31|35|Advanced renal disease

---

## NOTES

1. **Dates marked (estimated)** for EOI studies - update when confirmed
2. **Safe-D** is a Hub site study (Kiltearn) with 15,000 participants UK-wide
3. **EMBOLD, ELEVATE studies** are large global trials - local site recruitment targets may differ
4. **ZEUS** is closing in 2026 - verify LPLV date
5. All **CONTRACTED studies** should have SIV dates added when scheduled
6. **Pipeline studies** - wait for official award before adding

